| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-07-01 | Uniqure (The Netherlands) | $ 20 million (€ 14.6 million) | loan | Hercules Technology Growth Capital (USA) | Rare diseases - Genetic diseases | Loan |
| 2014-07-01 | Celyad previously known as Cardio3 Biosciences (Belgium) | €25 million | capital increase | Medisun International Limited (China) | Cardiovascular diseases | Capital increase |
| 2014-07-01 | Karo Bio (Sweden) | SEK 3.8 million (€0.4 million) | grant | Vinnova, Swedish Governmental Agency for Innovation Systems (Sweden) | Cancer - Oncology | Grant |
| 2014-06-30 | Ablynx (Belgium) | €41.7 million | private placement | domestic and international institutional investors | Cancer - Oncology - Hematological diseases - Inflammatory diseases - Lung diseases | Private placement |
| 2014-06-24 | Zealand Pharma (Denmark) | DKK 1 million (€0.13 million) | grant | Danish Innovation Fund (InnovationsFonden) (Denmark) | Metabolic diseases | Grant |
| 2014-06-24 | Fab’entech (France) | €5 million | fundraising | Auriga Partners (France), R2V (France), Rhône-Alpes Création (France), Sigma Gestion (France) and several companies investing on a personal level. | Infectious diseases | Fundraising |
| 2014-06-23 | Genfit (France) | €49.7 million | private placement | Metabolic diseases - Liver diseases - Inflammatory diseases | Private placement | |
| 2014-06-23 | Dimension Therapeutics (USA - MA) | $30 million | financing round | OrbiMed (USA - NY) Fidelity Biosciences (USA - MA) | Rare diseases | Financing round |
| 2014-06-19 | Innate Pharma (France) | €50 million | capital increase | specialist institutional investors | Cancer - Oncology - Inflammatory diseases | Capital increase |
| 2014-06-18 | Ziarco (UK) | £1.7m (€2.1 million) | grant | Technology Strategy Board (UK) | Dermatological diseases - Immunological diseases - Inflammatory diseases | Grant |
| 2014-06-17 | Pixium Vision (France) | €34.5 million | IPO | French and international institutional investors, French retail investors, Bpifrance Participations (France), Sofinnova (France), Abingworth (UK), Omnes Capital (France), Innobio (France) Seventure (France) | Ophtalmological diseases | IPO |
| 2014-06-17 | Cantargia (Sweden) | 20 MSEK | private placement of new shares | Cancer - Oncology | Private placement | |
| 2014-06-16 | Oxford BioMedica (UK) | £21.6 million | fundraising | Ophtalmalogical diseases - Genetic diseases - Rare diseases | Fundraising | |
| 2014-06-14 | Horizon Discovery (UK) LGC (UK) | £360,224 (€449887,5) | grant | Technology Strategy Board (UK) | Technology - Services | Grant |
| 2014-06-12 | Integragen (France) | €4.6 million | capital increase | Cancer - Oncology - CNS diseases | Capital increase | |
| 2014-06-10 | to-BBB (The Netherlands) | €10 million | series C financing round | new and existing investors | CNS diseases - Neurodegenerative diseases - Cancer - Oncology - Neuroinflammatory diseases | Series C financing round |
| 2014-06-06 | Nordic Nanovector (Norway) | NOK 250 million (€30.7 million) | private placement | existing shareholders | Cancer - Oncology | Private placement |
| 2014-06-06 | Trianta Immunotherapies, a Medigene subsidiary (Germany) | €380 000 | grant | Federal Ministry of Education and Research (BMBF) (Germany) | Cancer - Oncology - Autoimmune diseases | Grant |
| 2014-06-04 | Agalimmune (UK-USA) | undisclosed | Loxbridge Research (UK), Animatrix Capital (UK) | Cancer - Oncology | Milestone | |
| 2014-06-04 | Autifony Therapeutics (UK) | £2.2 million (€2.7 million) | grant | Technology Strategy Board (UK) | Otorhinolaryngology | Grant |
